 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes MINOCYCLINE increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"MINOCYCLINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: MINOCYCLINE: clinical_studies_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"14[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"14[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"15[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"15[0m[31m%"[0m[31m/[0m[31m> <tbody> <tr> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Subject&#x2019;s Weight [0m[1;31m([0m[31mlbs[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Subject&#x2019;s Weight [0m[1;31m([0m[31mkg[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Available Caplet Strength [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Actual MINOCYCLINE: clinical_studies_table: mg/kg<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> [0m
[31m<paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Dose <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m99[0m[31m &#x2013; [0m[1;31m131[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m45[0m[31m &#x2013; [0m[1;31m59[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m45[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1[0m[31m &#x2013; [0m[1;31m0[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m76[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule [0m
[31m"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m132[0m[31m &#x2013; [0m[1;31m199[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m60[0m[31m &#x2013; [0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m5[0m[31m &#x2013;[0m
[1;31m1[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m200[0m[31m &#x2013; [0m[1;31m300[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31m<paragraph>[0m[1;31m91[0m[31m &#x2013; [0m[1;31m136[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m135[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1.48[0m[31m &#x2013; [0m[1;31m0[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m99[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <[0m[31m/[0m[31mtbody[0m[31m> <[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: drug_interactions: [0m[1;31m7[0m[31m DRUG INTERACTIONS â€¢ Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. [0m[1;31m([0m[31m [0m[1;31m7.1[0m[31m [0m[1;31m)[0m[31m â€¢ The concurrent use of [0m
[31mtetracycline and methoxyflurane has been reported to result in fatal renal toxicity. [0m[1;31m([0m[31m [0m[1;31m7.3[0m[31m [0m[1;31m)[0m[31m â€¢ To avoid contraceptive failure, female patients are advised to use a second form of contraceptive during [0m
[31mtreatment with minocycline. [0m[1;31m([0m[31m [0m[1;31m7.5[0m[31m [0m[1;31m)[0m[31m [0m[1;31m7.1[0m[31m Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward [0m
[31madjustment of their anticoagulant dosage. [0m[1;31m7.2[0m[31m Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs [0m
[31min conjunction with penicillin. [0m[1;31m7[0m[31m. MINOCYCLINE: drug_interactions: [0m[1;31m3[0m[31m Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. [0m[1;31m7.4[0m[31m [0m
[31mAntacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations. [0m[1;31m7.5[0m[31m Low Dose Oral Contraceptives In a [0m
[31mmulti-center study to evaluate the effect of minocycline hydrochloride extended-release tablets on low dose oral contraceptives, hormone levels over one menstrual cycle with and without minocycline [0m
[31mhydrochloride extended-release tablets [0m[1;31m1[0m[31m mg/kg once-daily were measured. Based on the results of this trial, minocycline-related changes in estradiol, progestinic hormone, FSH and LH plasma levels, of[0m
[31mbreakthrough bleeding, or of contraceptive failure, cannot be ruled out. MINOCYCLINE: drug_interactions: To avoid contraceptive failure, female patients are advised to use a second form of [0m
[31mcontraceptive during treatment with minocycline. [0m[1;31m7.6[0m[31m Drug/Laboratory Test Interactions [0m[3;31mFalse[0m[31m elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.       [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: package_ndc         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_set_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: product_ndc         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: dosage_and_administration_table: <table [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"17[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"16[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"17[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"20[0m[31m%"[0m[31m/[0m[31m> <tbody> <tr> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule [0m
[31mToprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Patient&#x2019;s Weight [0m[1;31m([0m[31mlbs. MINOCYCLINE: dosage_and_administration_table: <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule [0m
[31mToprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Patient&#x2019;s Weight [0m[1;31m([0m[31mkg[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tablet Strength [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Actual mg/kg Dose<[0m[31m/[0m[31mcontent[0m[31m> [0m
[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m99[0m[31m-[0m[1;31m109[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m45[0m[31m-[0m[1;31m49[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m MINOCYCLINE: dosage_and_administration_table: Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m45[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1[0m[31m-[0m[1;31m0.92[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> [0m
[31m<[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m110[0m[31m-[0m[1;31m131[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m50[0m[31m-[0m[1;31m59[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m [0m
[31mBotrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m55[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph[0m[1;31m>[0m[1;31m1.10[0m[31m-[0m[1;31m0[0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: clinical_studies: [0m[1;31m14[0m[31m CLINICAL STUDIES The safety and efficacy of minocycline hydrochloride extended-release tablets in the treatment of inflammatory lesions of non-nodular [0m
[31mmoderate to severe acne vulgaris was assessed in two [0m[1;31m12[0m[31m-week, multi-center, randomized, double-blind, placebo-controlled, studies in subjects â‰¥ [0m[1;31m12[0m[31m years. The mean age of subjects was [0m[1;31m20[0m[31m years and [0m
[31msubjects were from the following racial groups: White [0m[1;31m([0m[1;31m73[0m[31m%[0m[1;31m)[0m[31m, Hispanic [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m, Black [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m, Asian/Pacific Islander [0m[1;31m([0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, and Other [0m[1;31m([0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m. In two efficacy and safety trials, a total of [0m[1;31m924[0m[31m subjects with [0m
[31mnon-nodular moderate to severe acne vulgaris received minocycline hydrochloride extended-release tablets or placebo for a total of [0m[1;31m12[0m[31m weeks, according to the following dose assignments. MINOCYCLINE: [0m
[31mclinical_studies: Table [0m[1;31m3[0m[31m: Clinical Studies Dosing Table Subjectâ€™s Weight [0m[1;31m([0m[31mlbs[0m[1;31m)[0m[31m Subjectâ€™s Weight [0m[1;31m([0m[31mkg[0m[1;31m)[0m[31m Available Caplet Strength [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m Actual mg/kg Dose [0m[1;31m99[0m[31m â€“ [0m[1;31m131[0m[31m [0m[1;31m45[0m[31m â€“ [0m[1;31m59[0m[31m [0m[1;31m45[0m[31m [0m[1;31m1[0m[31m â€“ [0m[1;31m0.76[0m[31m [0m[1;31m132[0m[31m â€“ [0m[1;31m199[0m[31m [0m[1;31m60[0m[31m â€“ [0m[1;31m90[0m[31m [0m[1;31m90[0m
[1;31m1.5[0m[31m â€“ [0m[1;31m1[0m[31m [0m[1;31m200[0m[31m â€“ [0m[1;31m300[0m[31m [0m[1;31m91[0m[31m â€“ [0m[1;31m136[0m[31m [0m[1;31m135[0m[31m [0m[1;31m1.48[0m[31m â€“ [0m[1;31m0.99[0m[31m The two primary efficacy endpoints were: [0m[1;31m1[0m[31m. Mean percent change in inflammatory lesion counts from Baseline to [0m[1;31m12[0m[31m weeks. [0m[1;31m2[0m[31m. Percentage of subjects with an [0m
[31mEvaluatorâ€™s Global Severity Assessment [0m[1;31m([0m[31mEGSA[0m[1;31m)[0m[31m of clear or almost clear at [0m[1;31m12[0m[31m weeks. Efficacy results are presented in Table [0m[1;31m4[0m[31m. MINOCYCLINE: clinical_studies: Table [0m[1;31m4[0m[31m: Efficacy Results at Week [0m[1;31m12[0m[31m Trial[0m
[1;31m1[0m[31m Trial [0m[1;31m2[0m[31m Minocycline Hydrochloride Extended-Release Tablets Placebo Minocycline Hydrochloride Extended-Release Tablets Placebo [0m[1;31m([0m[1;31m1[0m[31m mg/kg[0m[1;31m)[0m[31m [0m[31mN[0m[31m=[0m[1;31m300[0m[31m N = [0m[1;31m151[0m[31m [0m[1;31m([0m[1;31m1[0m[31m mg/kg[0m[1;31m)[0m[31m [0m[31mN[0m[31m= [0m[1;31m315[0m[31m N = [0m[1;31m158[0m[31m Mean Percent [0m
[31mImprovement in Inflammatory Lesions [0m[1;31m43.1[0m[31m% [0m[1;31m31.7[0m[31m% [0m[1;31m45.8[0m[31m% [0m[1;31m30.8[0m[31m% No. [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Subjects Clear or Almost Clear on the EGSA* [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m17.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m7.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m50[0m[31m [0m[1;31m([0m[1;31m15.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m15[0m[31m [0m[1;31m([0m[1;31m9.5[0m[31m%[0m[1;31m)[0m[31m *Evaluatorâ€™s Global Severity Assessment [0m
[31mMinocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory lesions [0m[1;31m([0m[31mbenefit or worsening[0m[1;31m)[0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: MINOCYCLINE has been shown to depress plasma prothrombin activity, which suggests that it could potentially increase the risk of bleeding. Patients who are on anticoagulant therapy may require[0m
[32ma downward adjustment of their anticoagulant dosage when taking MINOCYCLINE.[0m
[32mSOURCE: MINOCYCLINE label[0m
[32mEXTRACT_START_END: Because tetracyclines have been shown to depress [0m[32m...[0m[32m their anticoagulant dosage.[0m
*[1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: MINOCYCLINE has been shown to depress plasma prothrombin activity, [0m
[34mwhich suggests that it could potentially increase the risk of bleeding. Patients who are on anticoagulant therapy may require a downward adjustment of their anticoagulant dosage when taking [0m
[34mMINOCYCLINE.[0m
[34mSOURCE: MINOCYCLINE label[0m
[34mEXTRACT_START_END: Because tetracyclines have been shown to depress [0m[34m...[0m[34m their anticoagulant dosage.[0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether MINOCYCLINE increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that MINOCYCLINE has been shown to depress plasma prothrombin activity, which suggests that it could potentially increase the risk of bleeding. Patients on anticoagulant [0m
[32mtherapy may require a downward adjustment of their anticoagulant dosage when taking MINOCYCLINE, according to the MINOCYCLINE label."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"MINOCYCLINE has been shown to potentially increase the risk of bleeding by depressing plasma prothrombin activity."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does MINOCYCLINE increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether MINOCYCLINE increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that MINOCYCLINE has been shown to depress plasma prothrombin activity, which suggests that it could potentially increase the risk of bleeding. Patients on anticoagulant [0m
[34mtherapy may require a downward adjustment of their anticoagulant dosage when taking MINOCYCLINE, according to the MINOCYCLINE label."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"MINOCYCLINE has been shown to potentially increase the risk of bleeding by depressing plasma prothrombin activity."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does MINOCYCLINE increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether MINOCYCLINE increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that MINOCYCLINE has been shown to depress plasma prothrombin activity, which suggests that it could potentially increase the risk of bleeding. Patients on anticoagulant [0m
[31mtherapy may require a downward adjustment of their anticoagulant dosage when taking MINOCYCLINE, according to the MINOCYCLINE label.[0m
[31m        -----[0m
[31m        Final answer: MINOCYCLINE has been shown to potentially increase the risk of bleeding by depressing plasma prothrombin activity.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mMINOCYCLINE has been shown to potentially increase the risk of bleeding by depressing plasma prothrombin activity. This information is based on the MINOCYCLINE label, which indicates that patients on [0m
[32manticoagulant therapy may need to adjust their dosage when taking MINOCYCLINE.[0m
